Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum MERUS LABS INTERNATIONAL INC T.MSL

"Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products."

TSX:MSL - Post Discussion

MERUS LABS INTERNATIONAL INC > Challenging markets
View:
Post by whitehorn1 on Sep 18, 2015 5:59pm

Challenging markets

I thought of seriously buying this last year at this time. Merus had a good run - up but has corrected significantly and basically back at last years levels. Many challenges out there, although performed better than most, you have to wonder where this will trade in the next few months i.e. below 2 dollars or 2.50.
Comment by Craigbad on Sep 18, 2015 6:11pm
I would suggest having a look at the latest Thomson Resuters report. Msl has been downgraded to a 2 out of 10 and is now ranked in the bottom 15% of stocks to own. Concensus earnings estimates have been downgraded significantly to only $0.049 cents per share next year. Even at a 30 x forward multiple a price of $1.50 would still be expensive but worth a shot. Some will argue "ebitda" ...more  
Comment by Frostyfresh on Sep 18, 2015 6:17pm
People who look at EBITDA when buying stocks are idiots, especially for a company operating in multiple nations. Thus the 3.50 prices, thus the reality check.  Merus needs to make money. 
Comment by peter75 on Sep 18, 2015 6:53pm
Who knows what the profits will be craigbad you are a condescending piece of turd
Comment by lscfa on Sep 18, 2015 8:03pm
you bashing moron. eps is a piss poor metric because there is $6 million/qtr of amortization of intangible assets.
Comment by lscfa on Sep 18, 2015 8:48pm
latest qtr eps go from (0.02) to 0.05 by backing out amort. That's $0.20 annualized which means p/e is only 10x
Comment by curiousbuild on Sep 18, 2015 9:08pm
Craig, I am sorry to say that but it looks like you can use a girlfriend or something to keep yourself busy.. If someone posts about a bloating problem, will you jump and answer by technical problems too?  Make sure your woman is above 200dma average so nice and warm fluffy..  CB